HEXIMA LIMITED

ASX ANNOUNCEMENT

31 August 2026

2026 ANNUAL REPORT

MELBOURNE, AUSTRALIA (31 August 2026): Hexima Limited (ASX: HXL) provides the attached Annual Report for the financial year ended 30 June 2026.

This announcement is authorised for release to ASX by the Board of Hexima Limited.

Enquiries:

Leanne Ralph
Company Secretary
info@hexima.com.au

Hexima Limited

FINANCIAL REPORT

For the year ended 30 June 2026

CORPORATE DIRECTORY

Directors

Mr Geoffrey Kempler	Chairman and Managing Director
Mr Justin Yap	Non-Executive Director
Mr Phillip Hains	Non-Executive Director

Company Secretary

Ms Leanne Ralph

Registered Office

Hexima Limited
c/- Acclime, Level 3, 62 Lygon Street
Carlton, Victoria 3053, Australia

Share Registry

C/- MUFG Corporate Markets
a division of MUFG Pension & Market Services
Level 12, 680 George Street,
Sydney, NSW 2000, Australia

Auditor

William Buck
Level 20,
181 William Street
Melbourne Victoria 3000, Australia

Stock Exchange

Australian Securities Exchange Ltd

ABN

64 079 319 314

ASX code

HXL

CORPORATE GOVERNANCE STATEMENT

The Corporate Governance Statement is current at 30 June 2026 and appears at the end of this Financial Report. It was approved by the Board of Directors on 31 August 2026.

DIRECTORS' REPORT

The directors present their report together with the financial report of Hexima Limited ("the Company" or "Hexima") and of the Group, being the Company and its subsidiary, for the financial year ended 30 June 2026 and the auditor's report thereon.

DIRECTORS

The directors of Hexima at any time during or since the end of the financial year are:

Geoffrey Kempler BSc (Monash University); Grad Dip App Soc Psych (Swinburne University)

Chairman and Managing Director

Mr Kempler is a qualified psychologist with extensive experience in investment and business development. He was Founder and Chairman of the board of directors of Alterity Therapeutics Limited (ASX:ATH) from November 1997 until November 2025 and served as Chairman and non-executive director of Opthea Limited, an ASX and NASDAQ listed drug development company, from November 2015 until October 2020. He was Chairman of Ausbiotech, an Australian biotechnology organisation, from November 2021 until November 2023.

Mr Kempler has been a director of the Company since 5 September 2023.

Justin Yap B.Com (University of New South Wales)

Non-Executive Director

Mr Yap is a non-executive director of Wilhelm Integrated Solutions Pty Ltd, a leading supplier of integrated OR solutions to hospitals around Australia. Prior to this, he began his career in investment banking for Mosaic Risk Management Pty Ltd, a wholly owned subsidiary of Wilson HTM Limited specialising in derivatives risk management.

Mr Yap has been a director of the Company since 17 July 2018.

Phillip Hains B. Comm, CA, MBA (RMIT)

Non-Executive Director

Mr Hains is a Chartered Accountant with more than 30 years' experience providing businesses with accounting, administration, compliance and general management services. Until February 2026, he operated a specialist CFO Services division of Acclime Australia. A specialist in the public company environment, Mr Hains has advised and supported a number of company boards and their related committees. He now focuses on non-executive director roles. He served as a non-executive director of Radiopharm Theranostics Limited from March 2024 to November 2025 and is currently a non-executive director of Chimeric Therapeutics Limited, a position he has held since July 2023, and Frontier Digital Ventures Limited, since October 2025.

Mr Hains has been a director of the Company since 18 September 2023.

Company Secretary

Ms Leanne Ralph is the Company Secretary. Ms Ralph was appointed Company Secretary on 6 October 2021. She is an experienced Company Secretary with over 19 years in this field and holds this position for several ASX-listed entities. Ms Ralph is a fellow of the Governance Institute of Australia and a Graduate Member of the Australian Institute of Directors.

Directors' Meetings

The number of directors' meetings and the number of meetings attended and circular resolutions passed by each of the directors of the Company during the financial year are:

	BOARD MEETINGS		CIRCULAR RESOLUTIONS
	HELD	ATTENDED	SIGNED
Geoffrey Kempler	-	-	4
Justin Yap	-	-	4
Phillip Hains	-	-	4

DIRECTORS' REPORT

Due to the Company's limited activities and the small number of directors there were no operational sub-committees during the year and all critical decisions were made by the board by circular resolution.

PRINCIPAL ACTIVITIES

The principal activity of the Group during the financial year was the exploration of third-party transactions to realise the potential value of the Company's assets, including its biotech intellectual property portfolio.

OPERATING AND FINANCIAL REVIEW OF THE GROUP

Financial performance

	2026	2025
	$	$
Finance income	40,026	53,677
Net loss after tax attributable to members	(223,707)	(503,831)
Dividends	nil	nil

During the financial year ended 30 June 2026, the Company's shares remained suspended from official quotation on the ASX, having been suspended on 30 October 2024 following the cessation of its primary business activities. Under the ASX Listing Rules, the Company is expected to be removed from the Official List on 30 October 2026, at which time its shares will have been continuously suspended from quotation for two years.

During the financial year, having assessed its surplus capital position, the Company reduced its share capital by $1,002,237, distributing to each shareholder the amount of $0.006 (0.6 cents) per share and cancelling one share for every $0.008 (0.8 cents) distributed.

Despite this, Hexima remains committed to its biotech intellectual property portfolio, in which it retains royalty rights, while continuing to evaluate other opportunities as they arise.

Review of financial condition

The Group had net cash outflows from operating activities of $267,880 for the year ended 30 June 2026 compared with $637,190 for the prior year, with the variance largely reflecting the absence of due diligence costs in the current year.

The Group recorded a loss after tax of $223,707 for the year ended 30 June 2026. A loss after tax of $503,831 was recorded for the previous financial year.

Financial position

As at 30 June 2026, the Group had $258,320 in cash (2025: $1,535,814) and net assets of $236,269 (2025:$1,516,503)

SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

There were no other significant changes in the state of affairs of the Group that occurred during the financial year ended 30 June 2026.

DIVIDEND

The Company has not paid or declared any dividends during or since the end of the financial year ended 30 June 2026.

RISKS

The directors have identified the following risks which are relevant to the Group:

a) risk of finding a suitable buyer for its biotech intellectual property assets.

b) risk of ATO / AusIndustry finding research and development activities or expenditure to be ineligible and clawing back past claims with penalties and interest. However, it is the directors' view that there is no probable likelihood that any potential action may take place (see note 2(d) "Use of estimates and judgements" to the Consolidated Financial Statements).

DIRECTORS' REPORT

EVENTS SUBSEQUENT TO REPORTING DATE

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

ENVIRONMENTAL REGULATION

The Group's operations are not subject to any significant environmental regulations under either Commonwealth or State legislation. However, the board believes that the Group has adequate systems in place for the management of its environmental requirements and is not aware of any breach of those environmental requirements as they apply to the Group.

DIRECTORS' INTERESTS

Set out below are details of the interests of the directors at the date of this report in the shares of the Company, and rights or options over such instruments. Interests include those held directly and indirectly.

Director	Total shares	Options over shares
Geoffrey Kempler	-	837,500
Justin Yap (1)	-	134,125
Phillip Hains	-	-
Total	**-**	**971,625**

(1) A related party of Justin Yap holds 4,421,134 shares in the Company.

SHARE OPTIONS

Unissued shares under option

At the date of this report, unissued ordinary shares of the Company under option are:

Expiry Date	Exercise Price	Number
4 September 2028	$0.206	837,500
14 October 2030	$0.776	725,000
27 July 2031	$0.796	271,250
1 September 2031	$1.076	134,125
		1,967,875

Shares issued on exercise of options

No shares were issued on exercise of options during the year.

Unissued ordinary shares under option do not entitle the holder to participate in any new issues of securities, such as rights issues or bonus issues, prior to the exercise of those options. To actively participate in any future new issue of securities, option holders must have validly exercised their vested options and been registered as ordinary shareholders prior to the relevant record date for that issue

INDEMNIFICATION AND INSURANCE OF OFFICERS AND AUDITOR

The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the year, the Company paid no premiums in respect of any contract to insure the directors and executives of the Company against a liability to the extent permitted by the Corporations Act 2001. (2025: nil)

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor. During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

AUDITED REMUNERATION REPORT

Principles of Remuneration

The remuneration report details the key management personnel (KMP) remuneration practices of the Group. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity. For the financial year ended 30 June 2026, key management personnel comprised all directors.

Key Management Personnel - Directors	
Mr Geoffrey Kempler	Chairman and Managing Director
Mr Justin Yap	Non-Executive Director
Mr Phillip Hains	Non-Executive Director

Remuneration levels for key management personnel are set to attract and retain appropriately qualified and experienced directors and executives. When relevant, the board obtains independent advice on remuneration packages and reviews remuneration at least on an annual basis. No independent advice was sought from a consultant during the year.

Remuneration structures consider the capability and experience of key management personnel. Remuneration includes a mix of fixed and variable remuneration as well as short and long-term incentives.

Fixed Remuneration

Fixed remuneration consists of base salary, as well as employer contributions to superannuation funds.

Performance Linked Remuneration

Long term incentives may be provided as options over the Company's ordinary shares and other securities. Details are provided in the Directors' and Officers' Remuneration table in the Directors' Report.

Service Contracts

Executive Director

Mr Geoffrey Kempler was appointed as Chairman and Managing Director on 5 September 2023 and will hold this office until the next Annual General Meeting and then be subject to re-election at that meeting.

Pursuant to his service contract Mr Kempler is paid a fee of $52,000 per annum plus superannuation and was granted 3,350,000 options to acquire shares in the Company under the Company's Long Term Incentive Plan. Mr Kempler can resign at any time subject to reasonable notice.

The Company also entered into a Consultancy Services Agreement with Kemdev Pty Ltd, a related party of Geoffrey Kempler, on 5 September 2023 for the provision of consultancy services over 12 months for a fee of $100,000, of which $50,000 was paid on commencement of the agreement and $50,000 is payable upon completion by the Company of a merger or acquisition transaction.

AUDITED REMUNERATION REPORT – *(Continued)*

Non-Executive Directors

The terms of appointment for non-executive directors provide that board fees will be paid as agreed by the board and that equity compensation may be provided in lieu of cash compensation.

No non-executive director received any cash payments during the year and no share options were granted during the year.

During the 2025 financial year the Company returned $100,000 to Phillip Hains, being application monies received in the 2024 financial year for an intended share issue that was subsequently abandoned when the RealThing AI transaction did not proceed.

The Constitution provides that non-executive directors may be paid or provided fees or other remuneration for their services as a director of Hexima (including as a member of any directors' committee). The total amount or value of this remuneration must not exceed $500,000 (including mandatory superannuation) per annum or such other maximum amount determined by the Company in a general meeting.

A non-executive director may be paid remuneration for services outside the scope of ordinary duties of the director. Non-executive directors may also be paid expenses properly incurred in attending meetings or otherwise in connection with the Company's business. Additional "per diem" fees may be paid where services rendered are above normal requirements.

Non-executive directors have not received any cash payments since 1 January 2015 and have instead received equity compensation.

Other transactions with related parties of directors

During the year, payments for financial services from The CFO Solution HQ Pty Ltd (a related entity of Phillip Hains) of $6,050 (including GST) (2025: $46,322 (including GST)) were made and there was a current trade balance payable as at 30 June 2026 of nil (2025: nil). These transactions were made on normal commercial terms and at market rates.

At 30 June 2026 a related party of Justin Yap held 4,421,134 shares (2025: 17,684,540 shares)

Additional Information

The following table summarises the Group's financial performance for the five financial years ended 30 June 2026. The Board considers the Group's financial position and performance, together with the achievement of strategic objectives, when assessing remuneration arrangements and the value of equity-based incentives.

	2026 $	2025 $	2024 $	2023 $	2022 $
Total income	40,026	53,677	102,459	1,554,030	5,812,252
Loss before income tax	(223,707)	(503,831)	(933,873)	(1,918,886)	(10,020,761)
Loss after income tax	(223,707)	(503,831)	(933,873)	(1,918,886)	(10,020,761)
Basic EPS (cents per share)	(0.15)	(0.30)	(0.56)	(1.15)	(6.56)

AUDITED REMUNERATION REPORT–*(Continued)*

Directors' and Executive Officers' Remuneration

Details of the nature and amount of each major element of remuneration of each director of the Company and each key management personnel are:

	Short Term				Share based payments	Post employment			
2026	**Fixed Remuneration (Salary & Fees)**	**Termination Benefits**	**Leave Benefits**	**Health Cover**	**Expensing of Options held (1)**	**Superannuation**	**Total Remuneration**	**Value of Bonus as proportion of remuneration (2)**	**Value of options as proportion of remuneration**
Executive Director									
Geoffrey Kempler (2)	52,000	-	-	-	-	6,240	58,240	-	-
Non-executive Directors									
Justin Yap	-	-	-	-	-	-	-	-	-
Phillip Hains	-	-	-	-	-	-	-	-	-
Total	**52,000**	**-**	**-**	**-**	**-**	**6,240**	**58,240**		

2025									
Executive Director									
Geoffrey Kempler (2)	52,000	-	-	-	-	5,980	57,980	-	-
Non-executive Directors									
Justin Yap	-	-	-	-	-	-	-	-	-
Phillip Hains	-	-	-	-	-	-	-	-	-
Total	**52,000**	**-**	**-**	**-**	**-**	**5,980**	**57,980**	**-**	**-**

Notes in relation to the table of Directors' and Executive Officers' remuneration

1. The fair value of options is calculated at grant date using the Black-Scholes Pricing model and expensed over the period from grant date to vesting date. The value disclosed is the portion of the fair value of the options recognised in this reporting period.
2. Options are the only form of variable remuneration for directors. No options were granted during the year to any non-executive directors and no bonuses were paid.

DIRECTORS' REPORT

AUDITED REMUNERATION REPORT – *(Continued)*

Equity instruments

All options refer to options over ordinary shares of Hexima Limited, which are exercisable on a one-for-one basis.

Options over equity instruments granted as compensation

30 June 2026:

No options over equity instruments were granted as compensation during the year (2025: nil).

Options and rights over equity instruments

The movement during the reporting period in the number of options over ordinary shares in the Company held directly, indirectly or beneficially, by each key management person including their related parties, is as follows:

2026	Held at 1 July 2025	4 for 1 share cancellation	Held at 30 June 2026	Vested during the year	Vested and exercisable at 30 June 2026
Directors					
Geoffrey Kempler	3,350,000	(2,512,500)	837,500	-	837,500
Justin Yap	536,500	(402,375)	134,125	-	134,125
Phillip Hains	-	-	-	-	-
	3,886,500	(2,914,875)	971,625	-	971,625

During the financial year, the Company completed a 4-for-1 share cancellation and an equal reduction of capital of $0.006 per share. In accordance with ASX Listing Rules, the number of unissued shares under option was correspondingly adjusted on a 4-for-1 basis, and the exercise price of these options was inversely increased by a multiple of 4. This structural adjustment is required to maintain parity and ensure no material alteration to the economic balance between option holders and shareholders.

2025	Held at 1 July 2024	4 for 1 share cancellation	Held at 30 June 2025	Vested during the year	Vested and exercisable at 30 June 2025
Directors					
Geoffrey Kempler	3,350,000	-	3,350,000	-	3,350,000
Justin Yap	536,500	-	536,500	-	536,500
Phillip Hains	-	-	-	-	-
	3,886,500	-	3,886,500	-	3,886,500

DIRECTORS' REPORT

AUDITED REMUNERATION REPORT – *(Continued)*

Movement in shares

The movement during the reporting period in the number of ordinary shares in the Company held directly, indirectly, or beneficially by each key management personnel, including their related parties, is as follows:

2026	Held at 1 July 2025	Purchases	Purchased through exercise of options	4 for 1 share cancellation/ sales	Held at 30 June 2026
Directors					
Geoffrey Kempler	-	-	-	-	-
Justin Yap – related party (1)	17,684,540	-	-	(13,263,406)	4,421,134
Phillip Hains	-	-	-	-	-
	17,684,540	-	-	(13,263,406)	4,421,134

(1) The shares are held by a related party of Justin Yap and not held by him personally.

2025	Held at 1 July 2024	Purchases	Purchased through exercise of options	Sales	Held at 30 June 2025
Directors					
Geoffrey Kempler	-	-	-	-	-
Justin Yap – related party (2)	17,684,540	-	-	-	17,684,540
Phillip Hains	-	-	-	-	-
	17,684,540	-	-	-	17,684,540

(2) The shares are held by a related party of Justin Yap and not held by him personally.

End of Audited Remuneration Report

NON-AUDIT SERVICES

During the year William Buck performed no other services in addition to the audit and review of the financial statements for the year ended 30 June 2026.

Details of the amounts paid to the auditor of the Group for audit services are set out below:

	2026 $	2025 $
Audit and review of the financial statements	38,900	39,400

DIRECTORS' REPORT

LEAD AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001

The Lead Auditor's Independence Declaration is set out on page 28 and forms part of the Directors' Report for the year ended 30 June 2026.

This report is made pursuant to a resolution of the Directors.

Geoffrey Kempler

Chairman and Managing Director

Dated this 31st day of August 2026

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2026

		Consolidated	
		30 June	**30 June**
	Notes	**2026**	**2025**
Income		**$**	**$**
Finance income	4	40,026	53,677
		40,026	53,677
Expenses			
Employee benefits		(58,240)	(57,980)
Finance expense	4	(250)	(196)
Due diligence expenses		-	(242,143)
Corporate expenses	5	(205,243)	(257,189)
		(263,733)	(557,508)
Loss before income tax expense		**(223,707)**	**(503,831)**
Income tax benefit	2(d)	-	-
Loss after income tax for the year attributable to the owners of Hexima Limited		**(223,707)**	**(503,831)**
Other comprehensive income for the year, net of income tax		-	-
Total comprehensive loss for the year attributable to the owners of Hexima Limited		**(223,707)**	**(503,831)**
Earnings per share:			
Basic and diluted loss per share (cents)	8	(0.15)	(0.30)

The accompanying notes form part of these financial statements

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2026

		Consolidated	
	Notes	2026	2025
		$	$
CURRENT ASSETS			
Cash and cash equivalents		258,320	1,535,814
Other current assets	6	17,341	21,392
TOTAL CURRENT ASSETS		275,661	1,557,206
TOTAL ASSETS		275,661	1,557,206
CURRENT LIABILITIES			
Trade and other payables	7	39,392	40,703
TOTAL CURRENT LIABILITIES		39,392	40,703
TOTAL LIABILITIES		39,392	40,703
NET ASSETS		236,269	1,516,503
EQUITY			
Share capital	8	81,824,437	82,880,964
Reserves		1,077,656	1,077,656
Accumulated losses		(82,665,824)	(82,442,117)
TOTAL EQUITY		236,269	1,516,503

The accompanying notes form part of these financial statements

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2026

2026	Share Capital $	Equity Compensation reserve $	Accumulated Losses $	Total equity $
Opening balance at 1 July 2025	**82,880,964**	**1,077,656**	**(82,442,117)**	**1,516,503**
Total comprehensive loss for the period				
Net loss for the year	-	-	(223,707)	(223,707)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the year	-	-	(223,707)	(223,707)
Transactions with owners recorded directly in equity				
Share capital return **	(1,002,237)	-	-	(1,002,237)
Transaction costs related to capital return **	(54,290)	-	-	(54,290)
Total transactions with owners	(1,056,527)	-	-	(1,056,527)
Closing balance at 30 June 2026	**81,824,437**	**1,077,656**	**(82,665,824)**	**236,269**

** See Note 8

	Share Capital $	Equity Compensation reserve $	Accumulated Losses $	Total equity $
Opening balance at 1 July 2024	**82,880,964**	**1,088,027**	**(81,948,657)**	**2,020,334**
Total comprehensive loss for the period				
Net loss for the year	-	-	(503,831)	(503,831)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the year	-	-	(503,831)	(503,831)
Transactions with owners recorded directly in equity				
Options expired/lapsed	-	(10,371)	10,371	-
Total transactions with owners	-	(10,371)	10,371	-
Closing balance at 30 June 2025	**82,880,964**	**1,077,656**	**(82,442,117)**	**1,516,503**

The accompanying notes form part of these financial statements

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2026

	Note	Consolidated	
		30 June 2026	30 June 2025
		$	$
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash paid to suppliers and employees		(267,880)	(637,190)
Net cash used in operating activities	9	(267,880)	(637,190)
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest received		46,913	46,790
Net cash from investing activities		46,913	46,790
CASH FLOWS FROM FINANCING ACTIVITIES			
Return of share capital and associated transaction costs		(1,056,527)	-
Share application monies repaid		-	(100,000)
Net cash (used in) financing activities		(1,056,527)	(100,000)
Net decrease in cash and cash equivalents		(1,277,494)	(690,400)
Effect on movements in exchange rates on foreign currency denominated cash at bank		-	-
Cash and cash equivalents at 1 July		1,535,814	2,226,214
Cash and cash equivalents at 30 June		258,320	1,535,814

The accompanying notes form part of these financial statements

HEXIMA LIMITED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2026

1. REPORTING ENTITY

Hexima Limited (the “Company”) is a company domiciled in Australia and is a for-profit entity. The address of the Company’s registered office is c/- Acclime, Level 3, 62 Lygon Street, Carlton, Victoria, 3053. The consolidated financial statements of the Company as at and for the year ended 30 June 2026 comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”).

The Group was previously engaged in the research and development of plant-derived proteins for applications as human therapeutics but wound down these activities during the year ended 30 June 2023 and has since focused on the exploration of third-party transactions that will realise the potential value of the Company’s assets, including its intellectual property.

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES

(a) Basis of accounting

The financial report is a general purpose financial report which has been prepared in accordance with Australian Accounting Standards (AASBs) adopted by the Australian Accounting Standards Board (AASB) and the Corporations Act 2001. The consolidated financial report of the Group complies with International Financial Reporting Standards (IFRSs) and interpretations adopted by the International Accounting Standards Board (IASB).

The financial statements were approved by the board of directors on the date of signing the attached directors’ declaration.

(b) Basis of measurement

The financial report has been prepared on the basis of historical cost, except for share options.

(c) Functional and presentation currency

The financial statements are presented in Australian dollars, which is the Group’s functional and presentation currency. Unless otherwise stated, amounts are rounded to the nearest Australian dollar.

(d) Use of estimates and judgements

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Non-recognition of deferred tax assets
Deferred tax assets have not been recognised in respect of deductible temporary differences and tax losses because it is not probable that future taxable profit will be available against which the Group could utilise the benefits subject to passing the continuity of ownership and/or same business test. As at 30 June 2026 there were tax losses of $44,741,352 and temporary differences of $436,371 for which deferred tax assets have not been recognised.

Lodgement of research and development claims
In prior years, the entity has registered its research and development activities with AusIndustry and has accessed the refundable research and development tax offset for each claim year, which it has claimed through its submissions to the Australian Tax Office (ATO). Under this self-assessment program, AusIndustry and the ATO have the right to audit these claims at any point up to 4 years from the date of lodgement of the Research and Development Tax Incentive Schedule (via the income tax return) for each relevant financial year. If the research and development activities or expenditure are found to be ineligible during this review, the ATO may potentially clawback these claims with penalties and interest. It is the directors’ view that there is no probable likelihood that any potential action may take place based upon the following reasons:

- the industry environment in which the entity deals in is known for its research and development activities which have historically been supported through research and development claims; and
- the entity has a positive track record of not being selected for a compliance review by the ATO or AusIndustry.

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES (continued)

(d) Use of estimates and judgements *(continued)*

- the entity keeps appropriate substantiating documentation on file to ensure that its Tax Incentive claims can be supported with contemporaneous evidence in the event of an AusIndustry or ATO review.

(e) Principles of consolidation

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date control commences until the date control ceases. Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group transactions, are eliminated on consolidation.

(f) Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and deposits at call that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value. Term deposits with an original maturity of three months or less are included as cash equivalents; longer-dated term deposits are classified according to their contractual maturity and characteristics.

(g) Financial instruments

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the instrument. Financial assets are initially measured at fair value and subsequently measured in accordance with their classification under AASB 9 Financial Instruments. Financial liabilities are initially measured at fair value and subsequently at amortised cost unless otherwise required by AASB 9.

(h) Impairment / expected credit losses

The Group recognises loss allowances for expected credit losses on financial assets measured at amortised cost. Loss allowances are measured at an amount equal to lifetime expected credit losses where required by AASB 9, or otherwise at 12-month expected credit losses. At 30 June 2026 the Group had no material trade receivables and therefore no material customer-related expected credit loss exposure.

(i) Income tax

Income tax expense comprises current and deferred tax. Current and deferred tax are recognised in profit or loss except to the extent that they relate to items recognised directly in equity or other comprehensive income. Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the deductible temporary differences and tax losses can be utilised.

(j) Share based payments

The grant-date fair value of equity-settled share-based payment awards is recognised as an expense, with a corresponding increase in the equity compensation reserve, over the period in which the service and any non-market performance conditions are satisfied. The cumulative expense recognised reflects the Group’s estimate of the number of awards expected to vest. No adjustment is made for failure to satisfy market or non-vesting conditions where those conditions have been reflected in the grant-date fair value.

(k) New standards issued but not yet effective

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2026. The new Accounting Standard most relevant to the consolidated entity is AASB 18.

AASB 18 Presentation and Disclosure in Financial Statements is effective for annual reporting periods beginning on or after 1 January 2027. AASB 18 replaces AASB 101 Presentation of Financial Statements and introduces new requirements for the presentation of the statement of profit or loss, including defined categories and subtotals, together with enhanced requirements for management-defined performance measures and

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES (continued)

(k) New standards issued but not yet effective *(continued)*

aggregation and disaggregation of information. The Group is assessing the impact of AASB 18. The standard is not expected to affect recognition or measurement of the Group's assets, liabilities, income or expenses, but may affect presentation and disclosure in future financial statements.

3. SEGMENT REPORTING

Since winding down its biotechnology research and development activities in the year ended 30 June 2023, the Group's activities have consisted principally of corporate activities and the exploration of transactions intended to realise value from its remaining assets, including its biotechnology intellectual property portfolio.

The Board of Directors has been identified as the Group's chief operating decision maker (CODM) for the purposes of AASB 8 Operating Segments. The CODM reviews the Group's activities and financial performance on a consolidated basis for the purpose of allocating resources and assessing performance.

Accordingly, the Group has one operating and reportable segment, being the Corporate segment. The amounts reported in the consolidated financial statements represent the segment information reviewed by the CODM. All of the Group's activities during the year were conducted in Australia.

4. FINANCE INCOME AND EXPENSE

	Consolidated	
	2026	**2025**
	$	**$**
Interest income on at call deposits and cash at bank	40,026	53,677
Finance income	40,026	53,677
Foreign exchange loss	(250)	(196)
Finance expense	(250)	(196)

5. CORPORATE EXPENSES

	Consolidated	
	2026	**2025**
	$	**$**
Audit, tax, accounting and company secretarial costs	100,149	157,641
ASX, share registry and listing costs	59,725	51,210
Legal and professional fees	31,894	12,161
Other corporate and administration costs	13,475	36,177
	205,243	257,189

6. OTHER CURRENT ASSETS

	Consolidated	
	2026	2025
	$	$
Current		
Accrued interest receivable	-	6,887
GST receivable	5,600	1,745
Prepayments and other receivables	11,741	12,760
	17,341	21,392

7. TRADE AND OTHER PAYABLES

	Consolidated	
	2026	2025
Current	$	$
Trade payables	7,666	12,993
Other payables & accrued expenses	31,726	27,710
	39,392	40,703

8. CAPITAL AND RESERVES

Reconciliation of movement in capital and reserves.

Consolidated and the Parent Entity

Ordinary Shares	Number of Shares		Amount $	
	2026	2025	2026	2025
On Issue at 1 July	167,039,629	167,039,629	82,880,964	82,880,964
4 for 1 share cancellation	(125,279,785)	-	-	-
Return of capital	-	-	(1,002,237)	-
Transaction costs related to return of capital and 4 for 1 share cancellation	-	-	(54,290)	-
On issue at 30 June – fully paid	41,759,844	167,039,629	81,824,437	82,880,964

During the financial year the Company reduced its share capital by $1,002,237, distributing to each shareholder the amount of $0.006 (0.6 cents) per share and cancelling one share for every $0.008 (0.8 cents) distributed. Subject to fractional entitlements.

The Company does not have authorised capital or par value in respect of its issued shares. The holders of ordinary shares are entitled to receive dividends and the proceeds on a winding up and are entitled to one vote per share at general meetings of the Company.

8. CAPITAL AND RESERVES (continued)

Equity Compensation Reserve

The equity compensation reserve represents the accumulated amount of share options vested and to be vested to directors, key management personnel and other personnel under compensation schemes. Amounts are transferred from the reserve to accumulated losses when the relevant options expire or lapse.

	Number of options		Amount	
	2026	2025	2026 $	2025 $
On issue at beginning of year	7,871,500	8,154,000	1,077,656	1,088,027
Expired during period	-	(282,500)	-	(10,371)
4 for 1 option adjustment (1)	(5,903,625)	-	-	-
Total Reserve at year end	1,967,875	7,871,500	1,077,656	1,077,656

(1) During the financial year, the Company completed a 4-for-1 share cancellation and an equal reduction of capital of $0.006 per share. In accordance with ASX Listing Rules, the number of unissued shares under option was correspondingly adjusted on a 4-for-1 basis and the exercise price of these options was inversely increased by a multiple of 4.

Earnings per Share

The Group's basic and diluted EPS are shown below:

	2026	2025
Net loss	$(223,707)	$(503,831)
Weighted average number of ordinary shares	145,415,995	167,039,629
Basic and Diluted EPS (cents per share)	**(0.15)c**	**(0.30)c**

Dilutive earnings per share is the same as basic earnings per share as potential ordinary shares shall be treated as dilutive when, and only when, their conversion to ordinary shares would decrease earnings per share or increase loss per share.

Capital management

Following the wind-down of the Group's research and development activities, the Board's primary capital management objective has shifted from funding operational growth to safeguarding residual assets, ensuring sufficient liquidity to meet ongoing creditor obligations, and realising the maximum potential value of the Group's residual assets, including its intellectual property.

During the financial year, having assessed the Group's surplus capital position, the Group returned the majority of its net assets to shareholders. The Board determined that this reduction of share capital was fair and reasonable to the Company's shareholders as a whole and did not materially prejudice the Group's ability to pay its creditors, in accordance with statutory requirements.

The Board continues to evaluate opportunities as they arise to realise the remaining intellectual property assets and to manage the residual capital base in a manner that protects creditor interests pending final resolution of the entity's affairs. The Group is not subject to externally imposed capital requirements.

8. CAPITAL AND RESERVES (continued)

Details of share-based payment arrangements

At 30 June 2026, the Group had the following share-based payment arrangements. All options are to be settled by physical delivery of shares. The terms and conditions of the share options granted as at 30 June 2026 are as follows:

Grant date / parties entitled	Number of instruments	Vesting conditions	Contractual life of options
Options granted 14 October 2020 to key management	437,500	Vesting upon continuous service until 14 October 2021	10 years
Options granted 14 October 2020 to key management	287,500	Tranche 1 25% vesting 14 October 2021, and monthly thereafter until 14 October 2025	10 years
Options granted 2 December 2021 to non-executive directors	210,250	Vesting upon continuous service until 27 July 2022	10 years
Options granted 2 December 2021 to executive directors	61,000	25% vesting 27 July 2022, and in equal monthly instalments thereafter until 27 July 2025	10 years
Options granted 2 December 2021 to non-executive director	56,000	Vesting upon continuous service until 1 September 2022	10 years
Options granted 2 December 2021 to non-executive director	78,125	Vesting in 36 equal monthly tranches from 1 October 2021 until fully vested 1 September 2025	10 years
Options granted 5 September 2023 to executive director	837,500	Vesting immediately	5 years
Total share options	1,967,875		

The number and weighted average exercise prices of share options are as follows:

	Weighted average exercise price	Number of options	Weighted average exercise price	Number of options
	2026	2026	2025	2025
Outstanding at 1 July	$0.15	7,871,500	$0.17	8,154,000
Expired during the period	-	-	$1.00	(282,500)
4 for 1 option adjustment	$0.60	(5,903,625)	-	-
Outstanding at 30 June	$0.56	1,967,875	$0.17	7,871,500

No options were granted or exercised during the year and all options have been fully vested.

The options outstanding at 30 June 2026 have various exercise prices ($0.206, $0.776, $0.796, and $1.076) and a weighted average remaining contractual life of 3.6 years.

9. NOTES TO THE STATEMENT OF CASH FLOWS

Reconciliation of cash flows from operating activities

	Consolidated	
	2026	**2025**
Cash flows from operating activities	**$**	**$**
Loss for the year	(223,707)	(503,831)
Adjustments for:		
Interest received – classified as an investing activity	(46,913)	(46,790)
Operating loss before changes to working capital	(270,620)	(550,621)
Decrease in trade and other receivables and prepayments	4,051	21,398
(Decrease) in payables and employee benefits	(1,311)	(107,967)
Net cash used in operating activities	(267,880)	(637,190)

10. AUDITOR'S REMUNERATION

	Consolidated	
a. Audit Services	**2026**	**2025**
Auditors of the Company	$	$
- Audit of the annual financial report	25,500	26,000
- Review of half year financial statements	13,400	13,400
	38,900	39,400

The auditor for the current and prior year was William Buck Audit (Vic) Pty Ltd

11. FINANCIAL INSTRUMENTS AND RISKS

Financial Risk Management Policies

The Group's financial instruments consist of cash, on-call deposits, payables and credit card facilities. The carrying amounts of these instruments as at 30 June are as follows:

	2026	**2025**
Financial assets	$	$
Cash at bank	135,390	17,058
On-call deposit	122,930	55,447
Term deposits	-	1,463,309
	258,320	1,535,814
Financial liabilities		
Trade payables	7,666	12,993
Other items included in other payables and accrued expenses	29,300	26,495
	36,966	39,488

11. FINANCIAL INSTRUMENTS AND RISKS (continued)

Financial Risk Management Policies (continued)

The Group also has a credit card facility with a limit of $40,000 (2025: $40,000). The facility was undrawn at 30 June 2026 and 30 June 2025 and therefore is not included in financial liabilities above.

Interest rate risk

The Group is exposed to interest rate risk on its on-call deposit (floating rate) and term deposits (fixed rate). As at 30 June 2026, the interest rate on the on-call deposit was 1.4% (2025: 1.45%). Term deposits were held during the year to manage surplus working capital but had matured by 30 June 2026. The weighted average interest rate on term deposits held at 30 June 2025 was 3.95%. Credit card debts are paid by due date, and no interest charges were incurred during the year ended 30 June 2026 (30 June 2025: nil)

Credit Risk

Credit risk is the risk of financial loss to the Group if a counterparty to a financial instrument fails to meet its contractual obligations. The Group's principal credit exposure at 30 June 2026 arises from cash and deposits held with financial institutions. The Group manages this exposure by placing funds with reputable Australian financial institutions and monitoring its cash balances and counterparties.

The Group had no material trade receivables at 30 June 2026 and no material customer-related expected credit loss exposure. Accordingly, no material expected credit loss allowance was recognised at 30 June 2026 (2025: nil).

Liquidity Risk

Liquidity risk relates to the risk that the Group does not have available working capital to pay debts as and when they fall due. This risk is managed through cash flow forecasting and ongoing monitoring of available cash resources and expected expenditure.

At 30 June 2026, the Group's financial liabilities were payable within 60 days (June 2025: 60 days). The contractual undiscounted cash flows of those liabilities approximate their carrying amounts because of their short-term nature. The Group had no borrowings at 30 June 2026. (2025: nil)

12. CONTINGENCIES

The directors consider that the Group had no material contingent liabilities as at 30 June 2026 (30 June 2025: nil).

13. RELATED PARTIES

Directors

The following were key management personnel of the Group and the Company at any time during the reporting period and unless otherwise indicated were directors for the entire period:

Chairman and Managing Director

Mr Geoffrey Kempler

Non-Executive Directors

Mr Justin Yap

Mr Phillip Hains

The key management personnel compensation included in 'employee benefits expense' is as follows:

	Consolidated	
	2026	**2025**
	$	**$**
Short term employee benefits	52,000	52,000
Post employment benefits	6,240	5,980
Share based payments	-	-
	58,240	57,980

13. RELATED PARTIES (continued)

Non-remuneration related party transactions

The Company also entered into a Consultancy Services Agreement with Kemdev Pty Ltd, a related party of Geoffrey Kempler, on 5 September 2023 for the provision of consultancy services over 12 months for a fee of $100,000, of which $50,000 was paid on commencement of the agreement and $50,000 is payable upon completion by the Company of a merger or acquisition transaction.

During the year, payments for financial services from The CFO Solution HQ Pty Ltd, a member of Acclime Australia, and a related entity of Phillip Hains, of $6,050 (including GST) (2025: $46,322 (including GST)) were made and there was a current trade balance payable as at 30 June 2026 of nil (2025: nil)

All transactions were made on normal commercial terms and at market rates.

During the 2025 financial year, the Company returned $100,000 to Phillip Hains, being application monies received in the 2024 financial year for an intended share issue that was subsequently abandoned when the RealThing AI transaction did not proceed.

14. GROUP ENTITIES

	Country of incorporation	Ownership Interest	
Parent Entity		**2026**	**2025**
Hexima Limited	Australia	N/A	N/A
Significant subsidiaries			
Hexima Operations USA, Inc	USA	100%	100%

15. PARENT ENTITY DISCLOSURES

	2026	2025
Result of the Parent Entity	**$**	**$**
Loss for the period	(223,212)	(503,537)
Other comprehensive income	-	-
Total comprehensive loss for the period	(223,212)	(503,537)
Financial Position of the Parent Entity at year end		
Current assets	275,509	1,556,556
Total assets	275,509	1,556,556
Current liabilities	39,392	40,701
Total liabilities	39,392	40,701
Net assets	236,117	1,515,855
Total equity of the Parent entity comprising of:		
Share capital	81,824,437	82,880,964
Reserves	1,077,656	1,077,656
Accumulated losses	(82,665,976)	(82,442,765)
Total equity	236,117	1,515,855

15. PARENT ENTITY DISCLOSURES (continued)

The parent entity had no guarantees in relation to the debts of its subsidiaries at 30 June 2026 (2025: nil), no contingent liabilities at 30 June 2026 (2025: nil), and no contractual commitments for the acquisition of property, plant and equipment at 30 June 2026 (2025: nil).

16. SUBSEQUENT EVENTS

No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years

CONSOLIDATED ENTITY DISCLOSURE STATEMENT AS AT 30 JUNE 2026

		Bodies corporate		Tax residency	
Entity name	**Entity type**	**Country of incorporation**	**% of share capital held**	**Australian or foreign**	**Foreign jurisdiction**
Hexima Limited	Body Corporate	Australia	N/A	Australian	N/A
Hexima Operations USA, Inc	Body Corporate	USA	100%	Foreign	USA

Basis of preparation

This consolidated entity disclosure statement (CEDS) has been prepared in accordance with the Corporations Act 2001 and includes information for each entity that was part of the Group as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements.

Determination of tax residency

Section 295 (3A)(vi) of the Corporations Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are different interpretations that could be adopted, and which could give rise to a different conclusion on residency.

In determining tax residency, the Group has applied the following interpretations:

Australian tax residency

The Group has applied current legislation and judicial precedent, including having regard to the Tax Commissioner's public guidance in Tax Ruling TR 2018/5.

Foreign tax residency

Where necessary, the Group has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with (see section 295(3A)(vii) of the Corporations Act 2001).

Partnerships and Trusts

None of the entities noted above were trustees of trusts within the Group, partners in a partnership within the Group or participants in a joint venture within the Group.

DIRECTORS' DECLARATION

1) In the opinion of the directors of Hexima Limited ("the Company"):

   a) The consolidated financial statements and notes that are set out on pages 13 to 26, are in accordance with the Corporations Act 2001, including:

      i) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the financial year ended on that date;

      ii) complying with Australian Accounting Standards and the Corporations Regulations 2001; and

   b) There are reasonable grounds to believe that the Company and Group will be able to pay their debts as and when they become due and payable.

2) The directors draw attention to Note 2(a) to the financial statements, which includes a statement of compliance with International Financial Reporting Standards.

3) The directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the Managing Director and the Chief Financial Officer for the financial year ended 30 June 2026.

4) The information disclosed in the attached consolidated entity disclosure statement is true and correct.

Signed in accordance with a resolution of the Directors:

Dated at Melbourne this 31st day of August 2026

Geoffrey Kempler
Chairman and Managing Director

William Buck
ACCOUNTANTS & ADVISORS

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the directors of Hexima Limited

As lead auditor for the audit of Hexima Limited for the year ended 30 June 2026, I declare that, to the best of my knowledge and belief, there have been:

— no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and

— no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Hexima Limited and the entities it controlled during the year.

William Buck

William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136

N. S. Benbow
Director
Melbourne, 31 August 2026

WilliamBuck
ACCOUNTANTS & ADVISORS

Independent auditor's report to the members of Hexima Limited

Report on the audit of the financial report

Our opinion on the financial report

In our opinion, the accompanying financial report of Hexima Limited (the Company) and its controlled entities (together, the Group) is in accordance with the *Corporations Act 2001*, including:

— giving a true and fair view of the Group's financial position as at 30 June 2026 and of its financial performance for the year then ended; and

— complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

What was audited?

We have audited the financial report of the Group, which comprises:

— the consolidated statement of financial position as at 30 June 2026,

— the consolidated statement of profit or loss and other comprehensive income for the year then ended,

— the consolidated statement of changes in equity for the year then ended,

— the consolidated statement of cash flows for the year then ended,

— notes to the financial statements, including material accounting policy information,

— the consolidated entity disclosure statement, and

— the directors' declaration.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For these financial statements, we did not identify any key audit matter to report in this Audit Report.

Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of:

— the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and

— the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001,* and

for such internal control as the directors determine is necessary to enable the preparation of:

— the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and

— the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf

This description forms part of our auditor's report.

Report on the Remuneration Report

Our opinion on the Remuneration Report

In our opinion, the Remuneration Report of Hexima Limited, for the year ended 30 June 2026, complies with section 300A of the *Corporations Act 2001*.

What was audited?

We have audited the Remuneration Report included in the directors' report for the year ended 30 June 2026.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

William Buck

William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136

N. S. Benbow
Director
Melbourne, 31 August 2026

ASX ADDITIONAL INFORMATION

Additional information required under ASX Listing Rule 4.10 and not shown elsewhere in the Annual Report is as follows. This information is current as at 20 July 2026.

Substantial shareholders

The names of the Substantial Shareholders listed as disclosed by notices submitted to the ASX as at 20 July 2026 are as follows:

Shareholder	Shares	Relevant interest
Balmain Resources Pty Ltd	7,061,046	16.91%
Dato Lim Sen Yap[1]	4,421,134	10.59%
Woobinda Nominees Pty Ltd and its associates[2]	3,598,606	8.62%
Total	15,080,786	36.11%

Note 1: Related party of Justin Yap, a Director of Hexima.

Note 2: Associated entities of G.F. O'Brien, a previous Director of Hexima.

Voting rights

Ordinary shares

In accordance with the Constitution each member present at a meeting whether in person, or by proxy, or by power of attorney, or in a duly authorised representative in the case of a corporate member, shall have one vote on a show of hands, and one vote for each fully paid ordinary share, on a poll.

Options

There are no voting rights attached to options.

Securities exchange

The Company is listed on the ASX. The home exchange is Sydney.

Distribution of shareholders

The distribution of issued capital is as follows:

Size of Holding	Number of Shareholders	Ordinary Shares	% of Issued Capital
100,001 and over	59	35,072,976	83.99
10,001 – 100,000	173	5,295,192	12.68
5,001 – 10,000	88	665,984	1.59
1,001 – 5,000	258	614,209	1.47
1 to 1,000	246	111,483	0.26
Total	**824**	**41,759,844**	**100.00**

ASX ADDITIONAL INFORMATION (CONTINUED)

Distribution of option holders

The distribution of unquoted options on issue is:

Size of Holding	Number of Option holders	Ordinary Options	% of Options on Issue
100,001 and over	6	1,936,625	98.41
10,001 – 100,000	1	31,250	1.59
5,001 – 10,000	-	-	-
1,001 – 5,000	-	-	-
1 to 1,000	-	-	-
Total	7	1,967,875	100.00

Twenty largest shareholders of quoted securities

The twenty largest shareholders of quoted equity securities are as follows:

	Name	Number of Ordinary Shares Held	Percentage of Quoted Shares
1	Cadex Petroleum Pty Limited	4,665,009	11.17
2	Dato Lim Sen Yap	4,421,134	10.59
3	Woobinda Nominees Pty Ltd	3,598,606	8.62
4	Mr Surinder Singh & Mrs Satwinder Kaur	3,130,956	7.50
5	Balmain Resources Pty Ltd	2,117,287	5.07
6	Lehav Pty Ltd	1,628,498	3.90
7	Citicorp Nominees Pty Limited	1,216,342	2.91
8	Mr Paul Orlin	937,500	2.24
9	Hugh Morgan	744,313	1.78
10	Huysmans Pty Ltd	726,565	1.74
11	Balmoral Financial Investments Pty Ltd	637,772	1.53
12	Marilyn Anderson	601,387	1.44
13	Medomai Pty Ltd	575,000	1.38
14	Terence Williamson & Jonine Jancey	546,853	1.31
15	Catherine Marjorie Clarke	503,634	1.21
16	Cranley Nominees Pty Ltd	501,918	1.20
17	Pioneer Hi-Bred International Inc.	500,000	1.20
18	Ausum Pty Ltd	461,202	1.10
19	La Trobe University	417,272	1.00
20	Dr Peter Bernard Cebon	366,726	0.88
	Top 20 Quoted Shareholders	28,297,974	67.76
	Balance of Register	13,461,870	32.24
	Total Equity Securities	**41,759,844**	**100.00**

ASX ADDITIONAL INFORMATION (CONTINUED)

Unquoted equity securities

The Company had 1,967,875 unquoted options issued under employee incentive schemes, on issue as at 20 July 2026

Restricted securities

There are no restricted securities on issue at 20 July 2026

Less than marketable parcels of ordinary shares

There are 724 shareholders with unmarketable parcels totaling 4,166,882 shares.

On-market Buy-backs

There is currently no on-market buy-back in relation to the Company's securities.

HEXIMA LIMITED

2026 CORPORATE GOVERNANCE STATEMENT

The Hexima Limited (**Hexima** or **Company**) Board of Directors (Board) is pleased to present Hexima's Corporate Governance Statement for 2026 (**Statement**). This Statement outlines our principal corporate governance practices in place against the 4th edition of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations (Governance Principles). Our governance policies and practices are reflected in this Statement as well as our Appendix 4G.

This Statement was approved by the Company's board on 31 August 2026 and is current as at that date.

As Hexima's listed securities were suspended from quotation on the ASX on 30 October 2024 a number of the usual governance processes of the Company are not in place.

Principle 1: Lay solid foundations for management and oversight

Recommendation 1.1 – Roles and Responsibilities of the Board – not adopted

A listed entity should disclose a board charter setting out:

(a) the respective roles and responsibilities of its board and management; and

(b) those matters expressly reserved to the board and those delegated to management.

The Board operates under a formal Charter that sets out the functions reserved to the Board and provides for the delegation of functions to Board Committees and to senior management. The Board is accountable to our stakeholders for the management of the Company's business and affairs and as such, as outlined in the Board Charter, is responsible for demonstrating leadership, defining the Company's purpose, establishing strategic objectives, approving the Company's values and the Code of Conduct and oversight of the management of the Company.

Usually, the Chief Executive Officer (**CEO**) oversees the day-to-day management of the business, with delegated authority to manage the Company in accordance with the strategy, plans and policies approved by the board. As the operations of the Company have ceased, the Executive Chair and Managing Director, Mr Geoffrey Kempler, is carrying out the responsibilities which would ordinarily be assumed by the CEO.

Responsibilities specifically delegated to a CEO and those reserved for the Board are outlined in the Board Charter, which was previously reviewed on an annual basis to ensure that the division of functions between the Board and management continued to be appropriate for the needs of the Company.

The Board has delegated specific authority to two Board committees, which ordinarily assist the Board by examining various issues and making recommendations. A description of each committee and its responsibilities is set out under Principle 2 of this Statement.

Recommendation 1.2 – Appointment and Re-election of Directors - adopted

A listed entity should:

(a) undertake appropriate checks before appointing a director or senior executive, or putting someone forward for election, as a director; and

(b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.

When appointing directors to the board, appropriate checks are undertaken before their appointment.

The Board considers and formally resolves to support the election or re-election of directors to shareholders at general meetings/annual general meeting.

Shareholders are provided, in the relevant notice of meeting, with information in our possession relevant to assist them to make an informed decision on all directors standing for election or re-election. This information includes biographical details, covering relevant qualifications, experience, and skills directors bring to the Board, details of any other material directorships currently held by the candidate, the term of office currently served by the directors, a statement on the independence of the candidate and the reasons why, and a statement by the Board as to whether it supports the election or re-election of the candidate and a summary of the reasons why.

Directors are elected or re-elected in accordance with the Company Constitution and the ASX Listing Rules. At our 2025 Annual General Meeting, Mr Phillip Hains was elected by shareholders.

Recommendation 1.3 – Agreements with directors and senior managers – adopted

A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.

Non-executive directors are appointed pursuant to formal letters of appointment which, among other things, set out the key terms and conditions of the appointment, the Board's expectations in relation to the performance of the director, procedures for dealing with a director's potential conflict of interest and the disclosure obligations of the director, together with the details of the director's remuneration.

There are no senior executives currently employed by the Company, except for Mr Kempler, Executive Chair and Managing Director, who is formally engaged under an Appointment Letter.

Recommendation 1.4 – Accountability of the company secretary - adopted

The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.

The Board Charter expressly provides that the company secretary is directly accountable to the Board through the Chair on all matters to do with the proper function of the Board. All directors have access to the company secretary, who is appointed by, and accountable to, the Board on all governance matters.

Recommendation 1.5 – Diversity Policy – not adopted

A listed entity should:

- *(a) have and disclose a diversity policy;*
- *(b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and*
- *(c) disclose in relation to each reporting period:*
  - *i. the measurable objectives set for that period to achieve gender diversity;*
  - *ii. the entity's progress towards achieving those objectives; and*
  - *iii. either:*
    - *(A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined "senior executive" for these purposes); or*
    - *(B) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "gender Equality Indicators", as defined in and published under that Act.*

If the entity is in the S&P/ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.

The Company has adopted a Diversity Policy.

The Diversity Policy provides a framework for the Company to establish measurable objectives for achieving gender diversity, however, to date, the board has determined that it is not necessary to establish these objectives.

Our board will consider establishing measurable objectives for achieving gender diversity at the appropriate time. If these objectives are established, they will be disclosed as required under this Recommendation.

As at 30 June 2026, the respective proportions of women in the organisation are as follows:

	Female representation	
	2026	**2025**
Board Directors	**0%**	0%
Executives	**0%**	0%

Recommendation 1.6 – Evaluation of the performance of the board, its committees and individual directors – not adopted

A listed entity should:

(a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and

(b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.

Our Remuneration and Nomination Committee is ordinarily responsible for the development and implementation of a process for evaluating the performance of the board, committees and directors. This process has not yet been defined and may be re-considered at an appropriate time.

Given the Company has now ceased operations, a performance evaluation has not been deemed necessary.

Recommendation 1.7 – Evaluation of the performance of senior executives – not applicable therefore not adopted

A listed entity should:

(a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and

(b) disclose, in relation to each reporting period, whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.

The Company currently has no senior executives employed and therefore, recommendation 1.7 is not applicable.

Principle 2: Structure the board to add value

As at the date of this report there were three directors on our Board. Table 1 below sets out each director, the commencement of their tenure, and their status as an independent or non-independent director.

Table 1

Director	Tenure commencement	Independent / Non-independent
Mr Geoffrey Kempler	05 September 2023	Non-independent, executive director
Mr Phillip Hains	18 September 2023	Independent, non-executive director
Mr Justin Yap	17 July 2018	Non-independent, non-executive director

Directors' qualifications and experience are contained in the Directors' Report in our Annual Report, including details of their other listed entity directorships.

The ultimate responsibility for the oversight of the operations of the Company rests with the board. However, the board may discharge any of its responsibilities through committees of the board.

The board has established the following standing committees:

- Audit and Risk Management Committee; and
- Remuneration and Nomination Committee.

Each of these committees operates in accordance with specific charters approved by the board.

As the Company has ceased its former operating activities, the Committees have not been functioning as they ordinarily would and are currently dormant.

The number of scheduled board and committee meetings held during the year ending 30 June 2026 and the number of meetings attended by each of the directors is set out in our 2026 Annual Report.

Recommendation 2.1 – Nomination Committee – not adopted

The board of a listed entity should:

(a) have a nomination committee which:

(1) has at least three members, a majority of whom are independent directors; and

(2) is chaired by an independent director,

and disclose:

(3) the charter of the committee;

(4) the members of the committee; and

(5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or

(b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.

The board has established a Remuneration and Nomination Committee which operates under a charter approved by the board.

As noted earlier in this Statement, this committee is currently dormant.

Recommendation 2.2 – Board skills matrix – not adopted

A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.

The board has determined that the establishment of a Board Skills Matrix at this time is not appropriate, given the current position of the Company.

Directors' qualifications and experience are contained in the Directors' Report in our Annual Report. In addition to the skills and experience of directors, the board considers that each director has the following attributes:

- Honesty and integrity;
- The ability to think strategically;
- The time available to devote to Hexima's business;
- A willingness to question and challenge; and
- A commitment to the highest standards of governance.

All directors are expected to use their range of relevant skills, knowledge and experience and to apply their judgement to all matters discussed at Board meetings.

Recommendations 2.3 and 2.4 – Director independence – 2.3 is adopted; 2.4 is not adopted

A listed entity should disclose:

(a) the names of the directors considered by the board to be independent directors;

(b) if a director has an interest, position, association or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, association or relationship in question and an explanation of why the board is of that opinion; and

(c) the length of service of each director.

A majority of the board of a listed entity should be independent directors.

As indicated in Table 1 above, Mr Phillip Hains has been determined as being independent as at the date of this Statement. Our Board has made this assessment on the basis that he has not been employed in an executive capacity by the Company within the last three years, has not had a material business relationship with the Company within the last three years, is not a substantial holder of Hexima shares and does not fall within any other criteria listed in Box 2.3 of the ASX Governance Principles.

Mr Geoffrey Kempler is considered non-independent due to his executive role within the business. Mr Justin Yap is also considered non-independent as he is a related party of a substantial shareholder in the Company.

Based on this assessment, the Board does not currently have a majority of independent directors.

The term of office held by each director in office at the date of this statement is outlined earlier in this Statement.

Recommendation 2.5 – not adopted

The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.

As noted earlier in this Statement, Mr Geoffrey Kempler is the Executive Chair and Managing Director of the Company. The Company has no current requirement for a full time CEO, and therefore Mr Kempler is fulfilling this role.

The Chair's role is outlined in the Board Charter.

Recommendation 2.6 – not adopted

A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.

A director induction and orientation program was previously in place. This has been suspended and will be reinstated at the appropriate time.

Principle 3: Act ethically and responsibly

Recommendation 3.1 – not adopted

A listed entity should articulate and disclose its values.

Given that the operations of the Company have ceased, the Company has not established values.

Recommendation 3.2 – partially adopted

A listed entity should:

(a) have and disclose a code of conduct for its directors, senior executives and employees; and

(b) ensure that the board or a committee of the board is informed of any material breaches of that code.

The Company has adopted a Code of Conduct (the **Code**) that provides a set of guiding principles which are to be observed by all employees of the Company. The Code applies to anyone who is an employee or works for the Company or its subsidiaries.

Any material breaches of the Code are reported through to the Board.

Recommendation 3.3 – partially adopted

A listed entity should:

(a) have and disclose a whistleblower policy; and

(b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy

The Company has adopted a Whistleblower Policy. Any material breaches of the Whistleblower Policy are reported through to the Board.

Recommendation 3.4 – partially adopted

A listed entity should:

(a) have and disclose an anti-bribery and corruption policy; and

(b) ensure that the board or a committee of the board is informed of any material breaches of that policy.

The Company has adopted an Anti-Bribery Policy. Any material breaches of the Anti-Bribery Policy are reported through to the Board.

Principle 4: Safeguard integrity in corporate reporting

Recommendation 4.1 – not adopted

The board of a listed entity should:

(a) have an audit committee which:

a. has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and

b. is chaired by an independent director, who is not the chair of the board,

and disclose:

c. the charter of the committee;

d. the relevant qualifications and experience of the members of the committee; and

e. in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or

(b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.

An Audit and Risk Management Committee has been established by the board to protect the integrity of financial reports as well as to monitor and review the effectiveness of the Company's structures in the areas of operational risk and legal and regulatory compliance.

The Audit and Risk Management Committee operates in accordance with a charter adopted by the board. The charter sets out the roles and responsibilities as well as the structure and composition of the committee. The responsibilities of the Audit and Risk Management Committee are outlined in its charter.

As noted earlier in this Statement, this committee is currently dormant.

Recommendation 4.2 - adopted

The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

The Company has a requirement that the CEO or equivalent and CFO or equivalent provide written assurance to the board, prior to approval of the Company's financial statements for each financial period, that in their opinion, the Company's financial records have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the Company's financial position and performance, and that this opinion has been formed on the basis of a sound system of risk management and internal control which operates effectively.

Recommendation 4.3 – adopted

A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.

The Company has a process in place to verify the integrity of any other financial or non-financial corporate reports not reviewed by the external auditor. Any periodic corporate reports, including the Appendix 4C and Quarterly Activity Reports receive the approval of the Board prior to release to the market. This approval is based on a review of all relevant information provided. The specific process for each periodic corporate report will vary depending on the release but generally involves management analysis, discussion and recommendation, backed up by supporting documentation.

Principle 5: Make timely and balanced disclosure

Recommendation 5.1 - adopted

A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under Listing Rule 3.1.

The Company has adopted a Continuous Disclosure Policy.

The objectives of this policy are to:

- outline the Company's obligations in relation to continuous disclosure;
- ensure that the Company is able to meet its continuous disclosure obligations under the ASX Listing Rules and the Corporations Act; and
- establish internal procedures so that all employees understand their obligations to ensure:
    - confidential information is protected; and
    - disclose price sensitive information to the CEO or Board.

The overarching principle of this policy is governed by Listing Rule 3.1, which requires the Company to immediately notify the ASX of any information that a reasonable person would expect to have a material effect on the price or value of Hexima's quoted securities, provided that the information does not fall within the exception to disclosure under the Listing Rules. The Policy provides for the exceptions to Listing Rule 3.1 as outlined in Listing Rule 3.1A.

Recommendation 5.2 - adopted

A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made

The Company has a process of ensuring that all material ASX announcements are distributed to directors immediately upon their release to the market.

Recommendation 5.3 - adopted

A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.

Any new and substantive investor presentation or analyst presentation is released to the ASX prior to the presentations being given.

Principle 6: Respect the rights of security holders

Recommendation 6.1 – not adopted

A listed entity should provide information about itself and its governance to investors via its website.

As noted in the introduction of this Statement, the investor relations section of the Company's website is currently dormant.

Recommendation 6.2 – not adopted

A listed entity should have an investor relations program to facilitate effective two-way communication with investors.

The Company is committed to maintaining direct, open and timely communications with all shareholders. Our board's policy is that shareholders are informed of all material developments that impact on the Company.

Information is communicated to shareholders through:

- regular releases of financial information, including quarterly, half-year and full-year financial results, and trading updates as required;
- disclosures to the ASX;
- responding to shareholder queries; and
- the Annual General Meeting.

Recommendation 6.3 – adopted

A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.

The Company's annual general meeting is convened once a year, usually October or November. In relation to its meetings of shareholders, an explanatory memorandum on the resolutions is included with the notice of meeting.

Shareholders are encouraged to participate in general meetings and we aim to choose a date, time and venue convenient to shareholders.

If shareholders are unable to attend a general meeting, they are encouraged to vote on the proposed resolutions by appointing a proxy. The proxy form included with a notice of meeting explains how to appoint a proxy. Online proxy voting is also available to shareholders.

Unless specifically stated in a notice of meeting, all shareholders are eligible to vote on all resolutions.

A transcript of the Chair's address and any investor presentation is released to the ASX upon the commencement of the annual general meeting and the outcome of voting on resolutions at the meeting is released to the market after the conclusion of the meeting.

Recommendation 6.4 - adopted

A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.

The Company's practice is that voting on each proposed resolution is conducted by poll.

Recommendation 6.5 - adopted

A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.

All shareholders have the option to receive communications electronically from and send communications to the Company's registry service provider MUFG.

Principle 7: Recognise and manage risk

Recommendation 7.1 – not adopted

The board of a listed entity should:

(a) have a committee or committees to oversee risk, each of which:

a. has at least three members, a majority of whom are independent directors; and

b. is chaired by an independent director, and disclose:

c. the charter of the committee;

d. the members of the committee; and

e. as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or

(b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.

The board is responsible for ensuring that sound risk management strategy and policies are in place. The board has delegated to the Audit and Risk Management Committee the responsibility for identifying and overseeing major risks and the establishment and implementation of the risk management system.

As noted earlier in this Statement, this committee is currently dormant.

Recommendation 7.2 – not adopted

The board or a committee of the board should:

(a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and

(b) disclose, in relation to each reporting period, whether such a review has taken place.

It is the responsibility of the Audit and Risk Management Committee to review and assess the Company's risk management framework annually and review the implementation, management and maintenance of appropriate enterprise-wide risk management systems, policies and procedures, reporting protocols and internal controls.

This process was not carried out during FY26 given that the Company has ceased its former operating activities.

Recommendation 7.3 – adopted

A listed entity should disclose:

(a) if it has an internal audit function, how the function is structured and what role it performs; or

(b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its risk management and internal control processes.

Due to the company ceasing its former operating activities, an internal audit function has not been established.

Currently, the Board is the body that evaluates risk management and internal control processes.

Recommendation 7.4 - adopted

A listed entity should disclose whether it has any material exposure to environmental and social risks and, if it does, how it manages or intends to manage those risks.

The Board does not believe that the Company has any material exposure to environmental and social risks. Specific risk disclosures are included in the Annual Report.

Principle 8: Remunerate fairly and responsibly

Recommendation 8.1 – not adopted

The board of a listed entity should:

(a) have a remuneration committee which:

(1) has at least three members, a majority of whom are independent directors; and

(2) is chaired by an independent director, and disclose:

(3) the charter of the committee;

(4) the members of the committee; and

(5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or

(b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.

The Board has established a Remuneration and Nomination Committee which operates pursuant to a charter.

As noted earlier in this Statement, this committee is currently dormant.

Recommendation 8.2 - adopted

A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.

The Company's remuneration policies and practices are disclosed in the Remuneration Report in the Annual Report.

Recommendation 8.3 - adopted

A listed entity which has an equity-based remuneration scheme should:

(a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and

(b) disclose that policy or a summary of it.

The Company has adopted a Security Trading Policy that is intended to explain the types of conduct in relation to dealing in securities that are prohibited and establish a best practice procedure for the buying and selling of securities that protects the Company's directors, officers, employees and management against the misuse of unpublished information that could materially affect the value of securities.

The Share Trading Policy sets out restrictions that apply to dealing with securities and defines "prohibited periods" during which Key Management Personnel, are unable to deal in Hexima's securities.

In all instances, buying or selling of shares is not permitted at any time by any person who possesses price- sensitive information.

The Security Trading Policy provides that Key Management Personnel must not enter into any transactions that operate to limit the economic risk associated with holding securities in the Company.

Approved by the Board on 31 August 2026